Wegovy is being widely studied and praised for its ability to support weight management in people who have a BMI of over 30, classifying them as obese. While the standard maintenance dose is 2.4 mg, clinical trials have introduced a higher 7.2 mg strength. This new option is designed for patients who have already moved through the full dose-escalation and may need stronger support to continue losing weight. But what kind of results could be expected from this higher dose?
Table of Contents
Clinical Trial Results
The most detailed insights come from the STEP-UP clinical trial, which studied adults with obesity but without diabetes. In this study, participants who received Wegovy 7.2 mg once weekly achieved an average weight loss of around 20–21% of their body weight after 72 weeks.
By comparison, participants on the 2.4 mg dose lost around 17–18%. Though this strength still shows signs of weight loss, it also proves that the 7.2mg strength will be especially beneficial for patients who have found their results falling short or growing stagnant on the current maintenance dose of 2.4mg.
Perhaps most notably, about one in three people on 7.2 mg lost 25% or more of their baseline body weight—a result that is rarely seen with weight-loss treatments currently on the market.
Why Does the Higher Dose Work Better?
The mechanism of action remains the same because it is the same medicine; it hasn’t been altered in any way. Semaglutide mimics the hormone GLP-1, which reduces appetite, slows digestion, and helps regulate blood sugar levels. The 7.2 mg dose simply provides a greater effect on these processes due to it containing more medication than the 2.4mg. This makes it easier for patients to sustain lifestyle changes and continue losing weight over time without plateauing before reaching their weight loss goals.
Safety and Side Effects
Side effects at 7.2 mg are generally similar to those at 2.4 mg, with nausea, vomiting, diarrhoea, and constipation being the most common. Because the dose is higher, some people may notice stronger gastrointestinal symptoms, especially during dose escalation due to the 7.2mg dose being three times that of the 2.4mg dose. However, this new strength of Wegovy is relatively safe, with most side effects reported as mild to moderate and improved with time, as well as adjustment to the dose.
What to Expect Moving Forward
While results are promising, it’s important to remember that Wegovy 7.2 mg is not yet approved in the UK. If it is authorised, healthcare professionals will determine who is eligible and how the new dose should be used. For patients struggling to reach their goals on 2.4 mg, the 7.2 mg dose may represent the next step in their weight-loss journey. Once this has finished its reviewing period and becomes available in the UK, our clinical team at Pharmacy Planet will help you to safely and correctly transition onto this new strength of Wegovy, and ensure that you are making the most out of your weight loss journey.
